Biomarkers for prostate cancer: who will benefit from local treatment, who harbors occult systemic disease and who needs treatment at all?

Author： Citrin Deborah   Camphausen Kevin A  

Publisher： Future Medicine

ISSN： 1752-0363

Source： Biomarkers in Medicine, Vol.7, Iss.6, 2013-12, pp. : 823-825

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patients with Stable Coronary Artery Disease Receiving Chronic Statin Treatment Who Are Undergoing Noncardiac Emergency Surgery Benefit from Acute Atorvastatin Reload

By  

Cardiology, Vol. 128, Iss. 3, 2014-05 ,pp. : 285-292

Karger

Access to resources Recommend Favorite

Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?

By  

Oncology, Vol. 92, Iss. 6, 2017-03 ,pp. : 317-324

Karger

Access to resources Recommend Favorite

Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapy

By  

CANCER, Vol. 121, Iss. 24, 2015-12 ,pp. : 4324-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Who?

By Miller Saul  

British Journal of General Practice, Vol. 61, Iss. 588, 2011-07 ,pp. : 468-468

Royal College of General Practitioners

Access to resources Recommend Favorite

Who introduced early treatment to orthodontics?

By Philippe Julien  

Journal of Dentofacial Anomalies and Orthodontics, Vol. 15, Iss. 1, 2012-03 ,pp. : 107-107

Edp Sciences

Access to resources Recommend Favorite